274 related articles for article (PubMed ID: 36793329)
1. Esketamine for treatment‑resistant depression: A review of clinical evidence (Review).
Vasiliu O
Exp Ther Med; 2023 Mar; 25(3):111. PubMed ID: 36793329
[TBL] [Abstract][Full Text] [Related]
2. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
[TBL] [Abstract][Full Text] [Related]
3. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
[TBL] [Abstract][Full Text] [Related]
4. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review.
Salahudeen MS; Wright CM; Peterson GM
Ther Adv Drug Saf; 2020; 11():2042098620937899. PubMed ID: 32782779
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review.
Sapkota A; Khurshid H; Qureshi IA; Jahan N; Went TR; Sultan W; Alfonso M
Cureus; 2021 Aug; 13(8):e17352. PubMed ID: 34447651
[TBL] [Abstract][Full Text] [Related]
8. Case report: Intranasal esketamine for severe major depressive disorder with psychotic features.
Carter M; Solsrud K; Mischel N
Front Psychiatry; 2022; 13():937996. PubMed ID: 35958651
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review.
Boudieu L; Mennetrier M; Llorca PM; Samalin L
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140113
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
[TBL] [Abstract][Full Text] [Related]
11. Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.
Di Vincenzo M; Martiadis V; Della Rocca B; Arsenio E; D'Arpa A; Volpicelli A; Luciano M; Sampogna G; Fiorillo A
Front Psychiatry; 2024; 15():1394787. PubMed ID: 38812489
[TBL] [Abstract][Full Text] [Related]
12. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
Samalin L; Rothärmel M; Mekaoui L; Gaudré-Wattinne E; Codet MA; Bouju S; Sauvaget A
Int J Psychiatry Clin Pract; 2022 Nov; 26(4):352-362. PubMed ID: 35174754
[TBL] [Abstract][Full Text] [Related]
13. Esketamine: A Novel Option for Treatment-Resistant Depression.
Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
[No Abstract] [Full Text] [Related]
14. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.
Wong S; Kwan ATH; Teopiz KM; Le GH; Meshkat S; Ho R; d'Andrea G; Cao B; Di Vincenzo JD; Rosenblat JD; McIntyre RS
J Affect Disord; 2024 Apr; 350():698-705. PubMed ID: 38244804
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Kryst J; Kawalec P; Pilc A
Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
[No Abstract] [Full Text] [Related]
16. A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.
Wang YT; Wang XL; Lei L; Guo ZY; Kan FF; Hu D; Gai C; Zhang Y
Eur J Clin Pharmacol; 2024 Feb; 80(2):287-296. PubMed ID: 38117332
[TBL] [Abstract][Full Text] [Related]
17. Intranasal esketamine: A novel drug for treatment-resistant depression.
Khorassani F; Talreja O
Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
[TBL] [Abstract][Full Text] [Related]
18. Esketamine for treatment resistant depression.
Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
[No Abstract] [Full Text] [Related]
19. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
